Li-Hua Sun1,2, Fu-Qiang Yang1, Chuan-Bao Zhang1, Yi-Ping Wu2, Jing-Shan Liang1, Shuai Jin1, Zheng Wang1, Hong-Jun Wang3, Zhao-Shi Bao4, Zheng-Xiang Yang2, Tao Jiang1,4,5,6. 1. Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. 2. Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China. 3. Department of Neurosurgery, 2nd affiliated hospital of Harbin Medical University, Harbin, China. 4. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 5. Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China. 6. China National Clinical Research Center for Neurological Diseases, Beijing, China.
Abstract
AIMS: To explore the prognostic and clinicopathological features of glioma with Paxillin (PXN) expression based on a large number of samples. METHODS: RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) database were obtained as discovery set. Three additional datasets were further obtained as validation sets. The protein expression pattern of PXN in glioma was measured by IHC. Kaplan-Meier survival and multivariate Cox analysis were used to estimate the survival distributions. Moreover, the functional annotation of PXN was also analyzed. RESULTS: In the discovery set, PXN overexpression was significantly associated with high-grade glioma as well as the higher mortality in survival analysis (log-rank test, P < 0.01). The results of the other validation datasets showed similar findings. PXN also served as an independent prognostic biomarker in glioblastoma patients. Functional assays showed that PXN contributed to glioma cell proliferation and invasion. CONCLUSION: PXN plays as an oncogene in glioma progression and suggests a new potential biotarget for therapy.
AIMS: To explore the prognostic and clinicopathological features of glioma with Paxillin (PXN) expression based on a large number of samples. METHODS: RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) database were obtained as discovery set. Three additional datasets were further obtained as validation sets. The protein expression pattern of PXN in glioma was measured by IHC. Kaplan-Meier survival and multivariate Cox analysis were used to estimate the survival distributions. Moreover, the functional annotation of PXN was also analyzed. RESULTS: In the discovery set, PXN overexpression was significantly associated with high-grade glioma as well as the higher mortality in survival analysis (log-rank test, P < 0.01). The results of the other validation datasets showed similar findings. PXN also served as an independent prognostic biomarker in glioblastomapatients. Functional assays showed that PXN contributed to glioma cell proliferation and invasion. CONCLUSION:PXN plays as an oncogene in glioma progression and suggests a new potential biotarget for therapy.
Authors: X Han; J E Stewart; S L Bellis; E N Benveniste; Q Ding; K Tachibana; J R Grammer; C L Gladson Journal: Oncogene Date: 2001-11-29 Impact factor: 9.867
Authors: N Belot; S Rorive; I Doyen; F Lefranc; E Bruyneel; R Dedecker; S Micik; J Brotchi; C Decaestecker; I Salmon; R Kiss; I Camby Journal: Glia Date: 2001-12 Impact factor: 7.452